Quality of life (QOL) is a very complex subject and is difficult to measure in elderly patients. Only a few tools have been validated in this Thus, there is an unmet need for both standardisation and co-ordination of QOL evaluation tools in genito-urinary cancers. The availability of good QOL tools would enable an increase in the efficiency of decision-making in these cancers where comparisons between the side effects of the different treatments are difficult.
The quality of life (QOL) of the sick is a very complex concept.
Different definitions have been proposed: "Quality of life is the subjective evaluation of life as a whole"; 1 and "Quality of life refers to patients' appraisal of and satisfaction with their current level of functioning compared to what they perceived to be possible or ideal". 2 The World Health Organization (WHO) has defined health as "A state of complete physical, mental and social wellbeing and not merely the absence of disease." 3 In the cancer setting, quality of life is measured to evaluate the consequences of the disease itself and of management interventions. Generally, QOL assessment in elderly cancer patients follows the same rules as in the younger population. Nevertheless, in the elderly, cancer is often associated with other chronic conditions (heart, pulmonary, neurological or neuro-psychological diseases) that also affect QOL. These chronic conditions are associated with a global impairment of elderly patients' heath status that is better evaluated by the Comprehensive Geriatric Assessment (CGA) procedure. 4 Clinical research on QOL has rarely focused on elderly cancer patients; specific instruments have been developed but is not yet validated in this population. Quality of life can be assessed by either generic or highly specific instruments. The Medical Outcome Study Short Form 36 (SF-36), for instance, has been designed to measure the general impact of a wide range of medical conditions on QOL as a whole 5 and the questionnaire has already been validated in the geriatric population. 6 On the other hand, since the cancer-specific questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 has been developed, 7 several other questionnaires specifically designed for particular types of cancers have been validated. 8 Recently, a specific module for the assessment of QOL in elderly cancer patients, the QLQ-ELD15 questionnaire, has been published, 9 though is not yet validated. We will review the background information on genito-urinary (GU) cancers and their clinical settings and the standard QOL questionnaires available for elderly cancer patients, namely the EORTC QLQ-C30
and SF-36 questionnaires and their use in elderly patients with GU cancers. Thereafter, we will review the current knowledge on QOL in elderly patients with specific GU cancers (prostate, bladder and renal cancers). As regards prostate cancers, we will focus on localised, hormone-sensitive (HSPC) and castration-resistant (CRPC) diseases.
PubMed searches have been performed to retrieve the literature on the different tools available and to count the number of articles published in the different settings and to select those that seem relevant. We have searched the terms 'quality of life', 'prostate cancer', 'bladder cancer', 'kidney or renal cancer', 'elderly' and the different tool names used within the titles and/or titles and abstracts of the articles. and SF-36 has been shown. 11 The EORTC Quality of Life Group has developed a QOL assessment tool combining a core module (QLQ-C30) and additional modules focused on different types of cancer. The QLQ-C30 tool has been shaped for use in patients involved in clinical trials. 12 It is noteworthy that few elderly patients enter clinical trials. 13 Therefore, the QLQ-C30 questionnaire has been designed and validated on populations of younger patients. On the other hand, the generic SF-36 questionnaire has been used in a broad range of populations. [14] [15] [16] [17] 
Comparison Between Quality of Life Scales in Elderly Patients
We recently published a study comparing QLQ-C30 7 and SF-36 5, 6 in a population of 87 male GU cancer patients aged 68-86 years (median 76 years). These patients were also evaluated for pain (Visual Analog 
Quality of Life Studies in Prostate Cancer and Specific Questionnaires -The Case of Elderly Patients
Prostate cancer is the GU cancer in which QOL has been studied most often; nevertheless, the specific situation of elderly patients is infrequently addressed. A PubMed search of titles with the terms Three groups of patients were studied: patients with non-metastatic prostate cancer starting ADT, the same patients but without ADT, and controls. Median age was 69 years (range 50-87 years), meaning that half of the patients were elderly; however, these patients were fit (few co-morbidities). The conclusions were that ADT has adverse effects on physical function but not on cognitive function. Interestingly, results of self-reported physical function tested with the SF-36 scale were consistent with objective measurements. Nevertheless, none of these patients had significant abnormalities when using the ADL or IADL indexes. None of the other self-reported QOL items of the SF-36 scale and mini-mental status 50 measures was abnormal. In this study, SF-36 appears to be a good tool to explore functional status. No similar study was conducted using the EORTC QOL tools. An interesting recent article studied the relationship between QOL and hypogonadism in cancer patients (except prostate cancer): QOL was measured by the FACT-P questionnaire; median age was 62 years. 51 The study revealed
Supportive Oncology 
Quality of Life in Elderly Patients with Bladder Cancer
Few studies have been published on the QOL consequences of intravesical treatment for superficial bladder tumours. Standard questionnaires such as SF-36 have been used in only a few studies: 59 the scores evaluating physical, social and role -emotional functioning decrease after the first transurethral resection and increase thereafter when transurethral resection is repeated four or more times. Other investigators have developed specific questionnaires to study the QOL outcome of these patients. 60 More studies have addressed the question of QOL consequences of radical treatments in patients with infiltrating bladder cancers using different questionnaires. The FACT questionnaire adapted for bladder cancer (FACT-BL) was used in 82 patients undergoing radical cystectomy and 177 patients receiving conservative treatment. 61 There were no differences in general QOL scores between treatment groups and between the two urinary diversion groups, but patients undergoing cystectomy had worse sexual function scores. QOL scores for patients receiving conservative treatment tended to decrease with increasing age. The SF-36 questionnaire was used to compare the QOL associated with ileal conduit and with continent orthotopic neobladder. 62, 63 No significant difference was found in scale scores between treatment groups.
Scale scores for role -physical functioning, social functioning and role -emotional functioning in both groups were significantly below the population norm. Patients with a neobladder who were 65 years old or older had significantly lower scores for role -physical functioning and role -emotional functioning than younger patients.
Nonetheless, in elderly patients with no additional morbidity, orthotopic neobladder replacement can be superior to ileal conduit. index was also used to evaluate bladder preservation and functional quality after concurrent chemoradiotherapy for muscle-invasive bladder cancer. 68 Concurrent chemoradiation therapy allowed bladder preservation with tumour control at eight years in 67 % of the patients. 
Quality of Life in Elderly Patients with Kidney Cancers
Only a few studies have addressed the question of QOL in renal cancer. 69 An interesting approach was proposed under the auspices of the Kidney Cancer Association (KCA). 70 The authors studied a composite QOL index involving demographics, medical history, 
Quality of Life in Elderly Patients with Urological Malignancies
in metastatic kidney cancer has included a specific study of QOL outcome. 72 Symptoms were measured by the FACT-Kidney Cancer Symptom Index (FKSI) and QOL by the FACT-G. At baseline and over time, there were no differences in mean FACT-G or FKSI scores between the sorafenib and placebo groups. FKSI single-item analysis showed that Sorafenib-treated patients reported significantly fewer symptoms and concerns (e.g. cough, fever, shortness of breath, ability to enjoy life, worry that condition will get worse) than patients receiving placebo. Only concern about treatment side effects favoured placebo. Total FKSI score at baseline predicted overall survival.
Practical Conclusions
A wide spectrum of QOL tools have been evaluated in different GU cancer trials and studies. Only a few have been specifically studied in elderly patients. To date, the only scales validated in the setting of elderly patients are the QLQ-ELD15 scale and more importantly, the SF-36 scale. However, the QOL scales most frequently used in GU cancers are FACT-G (and the FACT-P module), the EORTC QLQ-PR25 scale and PROSQOLI. These tools have essentially been developed in prostate cancer patients. Therefore, at the present stage of research on QOL in GU cancer patients, the standard scale to be used in elderly prostate cancer patients is clearly the EORTC QLQ-C30 plus QLQ-PR25
scale. The addition of QLQ-ELD15 remains to be validated in this setting. 
